BONISTA PF Prefilled Pen 2.4ml

Teriparatide

Advanced Anabolic Support of Bone Reconstitution

Teriparatide is a recombinant form derived from human parathyroid hormone itself. It is the exception since most of the treatments working against osteoporosis are only meant to inhibit the loss of bone while Teriparatide is this anabolic agent meant at inducing the active formation of new and very high-quality bone within the body. It is used primarily in extremely high-risk groups for fracture-preventive action and aiming high at raising the performance of BMD.

Key Therapeutic Indications
Severe Postmenopausal Osteoporosis: For those women having very high chances of spinal or hip fractures.
Primary Hypogonadal Osteoporosis in Men: To increase bone mass for men at high risk of fracture.
Glucocorticoid-Induced Osteoporosis: For patients on long-term steroid therapy (like Prednisone) that has weakened their bones.
Fracture Prevention: Main aim is to strengthen the micro-architecture of bones.

Mechanism of Action: How It Works

Teriparatide mimics the biological function of the six amino acids found from among the 34 amino acids of human parathyroid hormone.

While administered once daily in its cyclical regimen:

Osteoblast Activation: It causes osteoblasts (bone-forming cells) to work harder than osteoclasts (bone-resorbing cells).
Mineralization: It boosts the absorption of calcium from the intestines and reduces its excretion from the kidneys.
Structural Renewal: All these ultimately increase both cortical and trabecular bone mass, thus giving a much sturdier skeleton.

Safety & Administration Profile

Feature
Recommendation

Administration: Subcutaneous injection in either the abdominal wall or thigh.
Dosing Schedule: One daily injection for 24 months max.
Storage: Must be kept in the refrigerator at 2°C to 8°C. The pen should not freeze.
First Dose: Should be administered where the patient can sit or lie down in case of dizziness.

Potential Side Effects
Most of the side effects are only temporary, occurring as the body adjusts to the hormone:

Mild Nausea: Stomach upset occasionally post-injection.
Dizziness: Brief “light-headed” feel, usually within one hour of use.
Leg Cramps: Nuisance muscle aches or cramps.
Hypercalcemia: Only a temporary, slight increase in blood calcium levels.

Critical Precautions
Risk Posed by Osteosarcoma: Avoid use in patients with Paget’s disease of bone, unexplained elevated alkaline phosphatase levels, or prior skeletal radiation therapy.

Kidney Stones: Use with caution in patients with active or recent urolithiasis (kidney stones).

Usage Limit: Total lifetime use is generally limited to 24 months.

Transition Therapy: After completion, patients are usually switched to a bone-maintaining drug (e.g., bisphosphonates) to preserve newly formed bone.

Frequently Asked Questions (FAQs)

Q: Is Teriparatide the same as a calcium supplement?
No. Calcium is a building block, whereas Teriparatide is the “foreman” that signals the body to build new bone. Calcium supplementation is still required as advised by the doctor.

Q: How should I store the injection pen?
The pen must be refrigerated at all times except during use. After injection, return it immediately to the fridge. Do not leave it outside or in heat.

Q: What should I do if I miss a day?
Take it as soon as you remember on the same day. If it is close to the next dose, skip it. Never double dose.

Q: Why don't patients use it for more than 2 years?
Because maximum bone formation benefit is achieved within 18–24 months, and longer use does not add benefit. Safety data also limits duration.

Q: Will I feel the bone growing?
No direct sensation is felt. Progress is monitored using bone mineral density (DEXA) scans and bone turnover markers.

Medical Disclaimer: This content is for informational purposes only and does not replace medical advice. Teriparatide is a high-potency prescription medication and should only be used under specialist supervision.